Bożena Jaźwiec

ORCID: 0000-0003-3239-6161
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Angiogenesis and VEGF in Cancer
  • Immune Response and Inflammation
  • Cancer Mechanisms and Therapy
  • Peptidase Inhibition and Analysis
  • Multiple Myeloma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Erythrocyte Function and Pathophysiology
  • Monoclonal and Polyclonal Antibodies Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Cell Adhesion Molecules Research
  • Immunodeficiency and Autoimmune Disorders
  • Cell death mechanisms and regulation
  • Hematopoietic Stem Cell Transplantation
  • Kruppel-like factors research
  • Lipid Membrane Structure and Behavior
  • Cutaneous lymphoproliferative disorders research
  • T-cell and B-cell Immunology
  • Cytokine Signaling Pathways and Interactions
  • Hematological disorders and diagnostics

Wroclaw Medical University
2013-2023

University of Wrocław
2010-2023

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy
1987-2015

Szpital Kliniczny Nr 1 we Wrocławiu
2015

Université de Bordeaux
1995-2000

Centre National de la Recherche Scientifique
1997-2000

Research Center Borstel - Leibniz Lung Center
1991

Polish Academy of Sciences
1989

Recent studies have suggested that Th17 cells may play a role in the pathogenesis of acute myeloid leukemia (AML). This subset CD4+ is characterized by interleukin (IL)-17A and IL-17F production, which share strong homology, surface expression IL-23 receptor (IL-23R). The present study aimed to determine association between polymorphic features located within IL-17A, IL-23R genes disease susceptibility, progression response therapy. In addition, relationship variants plasma IL-17 levels...

10.1007/s00432-014-1674-7 article EN cc-by Journal of Cancer Research and Clinical Oncology 2014-05-02

Background. The extrathyroid, orbital manifestation of Graves' disease (GD)—Graves' orbitopathy (GO)—presents a difficult clinical problem. immunological status GO patients is still under investigation. aim this study was to assess the serum concentration interleukin 6 (IL-6), soluble receptor (sIL-6R), and CD8+CD28− lymphocytes in evaluate if these parameters were associated with activity. Patients. Thirty-nine (29 women 10 men, aged 24–71, mean 50.18) newly diagnosed GD enrolled study....

10.3109/07435800.2011.635622 article EN Endocrine Research 2012-04-10

PIM-2 is a proto-oncogene that encodes for serine/threonine kinase interacts with various signaling molecules. highly expressed in neoplastic tissues and leukemic lymphoma cell lines, which consistent its role during oncogenic transformation. The nuclear factor kappa B (NF-κB) pathway appears to be deregulated variety of tumors, sustained activity NF-κB leading apoptotic resistance tumor cells. aim this study was investigate whether expression altered acute myeloid leukemia (AML)...

10.5604/17322693.1052449 article EN Postępy Higieny i Medycyny Doświadczalnej 2013-06-07

Syndecan‐1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation B ‐lymphoid cells. Its prognostic value in ‐cell chronic lymphocytic leukemia ( ‐CLL) has not been evaluated so far. The serum concentration sCD138 and some angiogenesis‐involved cytokines: vascular endothelial growth factor (VEGF), basis fibroblast (bFGF), endostatin were studied 52 previously untreated patients with ‐CLL. We found that bFGF levels significantly higher ‐CLL...

10.1155/mi/2006/42394 article EN cc-by Mediators of Inflammation 2006-01-01

The PIM2 gene encodes the serine/threonine kinase involved in cell survival and apoptosis. aim of study was to evaluate expression acute myeloid leukemia (AML) examine its role apoptosis blastic cells. We analyzed 148 patients: 91 with AML, 57 lymphoblastic 24 healthy controls by Real-Time PCR Western blot. Inhibition human leukemic HL60 line performed RNAi rate analyzed. Our results indicate that overexpression AML is associated low complete remission rate, high-risk cytogenetics, shorter...

10.3109/10428194.2015.1124991 article EN Leukemia & lymphoma/Leukemia and lymphoma 2016-01-14

B-cell chronic lymphocytic leukemia (B-CLL) presents with progressive accumulation of monoclonal B cells in the peripheral blood, bone marrow and lymphoid organs. B-CLL is characterized by heterogeneous clinical outcome. The expression Toll-like receptors (TLRs) their association other prognostic factors patients remain unclear. aim our study was to evaluate TLR2, TLR4 TLR9 genes significance as biological markers B-CLL. Sixty newly diagnosed were evaluated. healthy control group included 20...

10.1007/s00005-016-0433-7 article EN cc-by Archivum Immunologiae et Therapiae Experimentalis 2016-12-01

Abstract There are several reports that angiogenesis plays important roles in hematological malignancies including acute myeloid leukemia (AML). Human interleukin‐17 (IL‐17) is a proinflammatory cytokine produced by activated CD4 T cells. IL‐17 potential role cell mediated angiogenesis. The of pathologic has not been evaluated yet. aim the study was to determine plasma level patients with AML. levels were measured ELISA samples taken from 68 adult AML before chemotherapy administered. In...

10.1111/j.1582-4934.2003.tb00250.x article EN other-oa Journal of Cellular and Molecular Medicine 2003-10-01

The role of angiogenesis in multiple myeloma (MM) pathogenesis is well established. Angiogenesis linked to the functional state endothelial junctions that are modulated by growth and activation cells. CD146 vascular endothelial-cadherin (VE-cadherin) cell adhesion molecules localized at junction. aim study was assess sVE-cadherin sCD146 serum levels MM patients. Forty-six untreated patients with were included this study. In addition, 23 46 analyzed again partial remission after initial...

10.1111/j.1365-2257.2006.00756.x article EN Clinical & Laboratory Haematology 2006-01-19

<b><i>Background:</i></b> Chronic myeloid leukemia (CML) biology seemed to be perfectly explored especially at the beginning of tyrosine kinase inhibitors era. Later years with imatinib and second-generation showed a variety resistance mechanisms it became obvious that bcr-abl chimeric gene is not only enemy fight. Some studies assumed decreased rate programmed cell death (apoptotic) primary mechanism by which BCR-ABL affects expansion leukemic clone in CML....

10.1159/000357373 article EN Acta Haematologica 2014-01-01

Abstract The aim of this study was to evaluate the phospholipid concentration in acute leukemia (AL) blast cells from peripheral blood (PBMC) and bone marrow (BMMC). In vitro 31P Nuclear Magnetic Resonance Spectroscopy (31P MRS) used. integral intensities resonant peaks concentrations PBMC BMMC were analyzed. Differences myeloblastic or lymphoblastic lines also evaluated. This investigation carried out on extracts 15 healthy volunteers 77 patients with AL (samples taken at moment diagnosis)....

10.2478/s11658-008-0032-7 article EN cc-by-nc-nd Cellular & Molecular Biology Letters 2008-10-06

Toll-like receptors play an important role in the host defense against microorganisms. Sepsis remains a common cause of mortality patients with acute myeloid leukemia (AML) treated intensive induction chemotherapy. The expression TLRs and their association development sepsis unclear. aim this study was to investigate associations between TLR2, TLR4 TLR9 occurrence chemotherapy for AML. A total 103 newly diagnosed AML were evaluated. Bone marrow samples taken before therapy. Using...

10.1007/s12032-014-0319-7 article EN cc-by Medical Oncology 2014-11-21

<b><i>Background and Purpose:</i></b> When choosing a cytoreduction method for patients suffering from essential thrombocythemia (ET), it is important to know the safety profile of medicine used. Few articles have been published about effects hydroxycarbamide (hydroxyurea, HU) anagrelide (ANA) on renal function in ET patients. This study largest analysis nephrotoxicity cytoreductive drugs used therapy so far, which additionally includes risk factors progression kidney...

10.1159/000513377 article EN Pharmacology 2021-01-01
Coming Soon ...